Opens in a new tab

Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_75/2023, 11 October 2023)

Date11 October 2023
CourtCFI
DivisionMunich (DE) Central Division - Section
Type of actionRevocation Action
Case number(s)UPC_CFI_75/2023
Registry referenceORD_579543/2023 · UPC_CFI_75/2023
PartiesASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE v. HELIOS K.K, RIKEN, OSAKA UNIVERSITY

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By procedural order of 11 October 2023 (UPC_CFI_75/2023, ACT_464985/2023), the judge-rapporteur of the Munich section of the Central Division, in Astellas Institute for Regenerative Medicine’s revocation action against EP 3 056 563 held by Healios, Riken and Osaka University, ruled that the Defence to Revocation was deemed served on the claimant on 29 September 2023. The order confirms that the notification generated by the case management system (CMS) amounts to service, with no specific communication from the Court required.

Question

Was the Defence, first filed through the wrong CMS workflow and then refiled through the « Defence » workflow, served on the claimant in the absence of a separate communication from the Registry, and if so on what date?

Decision

The parties are in principle obliged to use the CMS and its dedicated workflows, and it is their sole responsibility to file properly and on time. Submissions and correspondence outside the CMS should be kept to a minimum. The notification generated by the system is the « means of electronic communication » referred to in Rule 278.1 RoP, and no further « specific communications » from the Court are required. The defendants argued that the two-month period for the Reply had not started for want of such communications. The claimant had said it would treat 29 September 2023, the date of refiling, as the date of service. As the defendants raised no objection to that date, the Court accepted it. A request for panel review remains available within 15 days (Rule 333 RoP).

Key points for practice

Provisions applied

Rules of Procedure
Rules 4.1, 6.1(b), 9, 32, 51, 271.6, 278.1, 278.4, 278.5 and 333

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Revocation action.

Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_75/2023 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 21 September 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 September 2023) Revocation Action · UPC_CFI_75/2023

    La demande d'accès d'un tiers au mémoire introductif et à la lettre de signification est rejetée : l'éducation et la formation ne sont pas un motif légitime, et la lettre n'est ni une écriture ni une pièce.

  2. 11 October 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_75/2023, 11 October 2023) Revocation Action · UPC_CFI_75/2023
  3. 28 December 2023 Mathys & Squire v Astellas (CFI, 28 December 2023) Application RoP262.1 (b) · UPC_CFI_75/2023

    La demande d'accès de Mathys & Squire est mise en attente jusqu'à la décision de la cour d'appel sur la règle 262.1 b), à produire dans les trois semaines.

  4. 18 March 2024 Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 March 2024) Revocation Action · UPC_CFI_75/2023

    Le document D18 est admis sous réserve d'une réponse de la défenderesse avant le 11 avril 2024, la valeur du litige est fixée à 4 000 000 euros et l'audience confirmée au 25 juin 2024.

  5. 22 August 2024 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 22 August 2024) Application RoP262.1 (b) · UPC_CFI_75/2023

    Mathys & Squire obtient l'accès aux écritures et pièces de l'action en nullité close par transaction, après occultation des données personnelles et des informations confidentielles d'Astellas. L'appel est autorisé.

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
Le mémoire en défense à l'action en nullité est réputé signifié le 29 septembre 2023, la notification générée par le CMS valant signification au sens de la règle 278.1.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 056 563
Method of producing retinal pigment epithelial cell
recorded proprietor: Healios KK, RIKEN et University of Osaka NUC
Mentioned in the analysis (role not qualified)
Also mentioned in 7 other decision(s): Mathys & Squire v Astellas Institute for Regenerative Medicine (CFI, 4 · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 22 Au · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 23 Ju · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 M · Mathys & Squire v Astellas (CFI, 28 December 2023) · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 Se · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.